Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Annals of Oncology

• Publication date

  2017-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdx222PMID 32369879
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

  2019cited by this paper
• 26 – Preoperative Functional Evaluation of the Surgical Candidate

  2018cited by this paper
• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2018cited by this paper
• Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery

  2017cited by this paper
• Treatment-Related Toxicity in Patients with Early Stage Non-Small Cell Lung Cancer and Co-Existing Interstitial Lung Disease: A Systematic Review.

  2017influential reference
• Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017.

  2017cited by this paper
• Risk stratification based on screening history: the NELSON lung cancer screening study

  2017cited by this paper
• Precise Diagnosis of Intraoperative Frozen Section Is an Effective Method to Guide Resection Strategy for Peripheral Small-Sized Lung Adenocarcinoma.

  2016cited by this paper
• An Additional Step Toward Personalization of Surgical Care for Early-Stage Non-Small-Cell Lung Cancer.

  2016cited by this paper
• PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial.

  2016cited by this paper
• The smaller the better: a new concept in thoracic surgery?

  2016cited by this paper
• Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial.

  2016cited by this paper
• Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation.

  2016cited by this paper
• Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer.

  2016cited by this paper
• Lymph node involvement influenced by lung adenocarcinoma subtypes in tumor size ≤3 cm disease: A study of 2268 cases.

  2016cited by this paper
• Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer.

  2016cited by this paper
• Comprehensive Clinical Staging for Resectable Lung Cancer: Clinicopathological Correlations and the Role of Brain MRI

  2016cited by this paper
• Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Lymph Node Dissection in Clinical Stage I Lung Cancer: A Meta-Analysis and System Review.

  2016cited by this paper
• Factors influencing the concordance of histological subtype diagnosis from biopsy and resected specimens of lung adenocarcinoma.

  2016cited by this paper
• Lung Cancer Screening With Low-Dose CT: Implementation Amid Changing Public Policy at One Health Care System.

  2016cited by this paper
• The Natural History of Operable Non-Small Cell Lung Cancer in the National Cancer Database.

  2016cited by this paper
• Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

  2016cited by this paper
• Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-small Cell Lung Cancer by a Meta-Analysis.

  2016cited by this paper
• Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease.

  2016cited by this paper
• Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line?

  2016cited by this paper
• Evaluation of Pulmonary Nodules: Clinical Practice Consensus Guidelines for Asia.

  2016cited by this paper
• An Official American Thoracic Society/American College of Chest Physicians Policy Statement: Implementation of Low-Dose Computed Tomography Lung Cancer Screening Programs in Clinical Practice

  2016cited by this paper
• E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC--Outcomes based on chemotherapy subsets.

  2016cited by this paper
• Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens

  2016cited by this paper
• Lobectomy Versus Segmentectomy in Radiologically Pure Solid Small-Sized Non-Small Cell Lung Cancer.

  2016cited by this paper
• The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification

  2016cited by this paper
• Validation of High-Risk Computed Tomography Features for Detection of Local Recurrence After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer.

  2016cited by this paper
• Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer

  2016cited by this paper
• The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part‐Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

  2016cited by this paper
• The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

  2016cited by this paper
• Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer: A Systematic Review.

  2016cited by this paper
• The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

  2016cited by this paper
• Outcomes of Hypofractionated High‐Dose Radiotherapy in Poor‐Risk Patients with “Ultracentral” Non–Small Cell Lung Cancer

  2016cited by this paper
• An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice.

  2015cited by this paper
• Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non–Small-Cell Lung Cancer: Importance of Salvage Surgery

  2015cited by this paper
• Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT – the Nordic experience

  2015cited by this paper
• Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.

  2015cited by this paper
• The British Thoracic Society guidelines on the investigation and management of pulmonary nodules

  2015cited by this paper
• Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.

  2015cited by this paper
• A patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study

  2015cited by this paper
• Wedge resection and radiofrequency ablation for stage I nonsmall cell lung cancer

  2015cited by this paper
• Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons.

  2015cited by this paper
• Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.

  2015cited by this paper
• Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art.

  2015cited by this paper
• Standardized Uptake Values in the Primary Lesions of Non-Small-Cell Lung Cancer in FDG-PET/CT Can Predict Regional Lymph Node Metastases

  2015cited by this paper
• Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy

  2015cited by this paper
• Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis.

  2015cited by this paper
• The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

  2015cited by this paper
• Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS)

  2015cited by this paper
• Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ≤3 cm: accuracy and interobserver agreement

  2015cited by this paper
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

  2015cited by this paper
• Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

  2015cited by this paper
• Limited Resection Versus Lobectomy for Older Patients With Early-Stage Lung Cancer: Impact of Histology.

  2015cited by this paper
• Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

  2015cited by this paper
• Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).

  2015influential reference
• Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

  2015cited by this paper
• Overdiagnosis in low-dose computed tomography screening for lung cancer.

  2014cited by this paper
• Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer.

  2014cited by this paper
• Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

  2014cited by this paper
• Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening.

  2014cited by this paper
• Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality.

  2014cited by this paper
• Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: Implications for Surveillance

  2014cited by this paper
• Mediastinal Lymph Node Dissection versus Mediastinal Lymph Node Sampling for Early Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

  2014influential reference
• Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival.

  2014cited by this paper
• Salvage operation for late recurrence after stereotactic body radiotherapy for lung cancer: two patients with no viable cancer cells.

  2014cited by this paper
• Readmission after lung cancer resection is associated with a 6-fold increase in 90-day postoperative mortality.

  2014cited by this paper
• Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice.

  2014cited by this paper
• Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25.

  2014cited by this paper
• The N2 paradox: similar outcomes of pre- and postoperatively identified single-zone N2a positive non-small-cell lung cancer.

  2014cited by this paper
• Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma.

  2014cited by this paper
• The Effects of Increased Provision of Thoracic Surgical Specialists on the Variation in Lung Cancer Resection Rate in England

  2013cited by this paper
• Rib fracture after stereotactic radiotherapy for primary lung cancer: prevalence, degree of clinical symptoms, and risk factors

  2013cited by this paper
• Estimating overdiagnosis in low-dose computed tomography screening for lung cancer : a cohort study

  2013cited by this paper
• Surgical treatment of metachronous second primary lung cancer after complete resection of non-small cell lung cancer.

  2013cited by this paper
• Stereotactic ablative radiotherapy: A potentially curable approach to early stage multiple primary lung cancer

  2013cited by this paper
• Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review.

  2013cited by this paper
• Multidisciplinary Team-Based Approach for Comprehensive Preoperative Pulmonary Rehabilitation Including Intensive Nutritional Support for Lung Cancer Patients

  2013cited by this paper
• Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery.

  2013cited by this paper
• Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance.

  2013cited by this paper
• High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer.

  2013cited by this paper
• Methods for Staging Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2013cited by this paper
• Recurrence Dynamics for Non–Small-Cell Lung Cancer: Effect of Surgery on the Development of Metastases

  2012cited by this paper
• Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands.

  2012cited by this paper
• Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients.

  2012cited by this paper
• Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

  2012cited by this paper
• The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

  2012cited by this paper
• Lung-cancer related chest events detected by periodical follow-up CT after stereotactic body radiotherapy for stage I primary lung cancer: retrospective analysis of incidence of lung-cancer related chest events and outcomes of salvage treatment

  2012cited by this paper
• Root cause analysis of problems in the frozen section diagnosis of in situ, minimally invasive, and invasive adenocarcinoma of the lung.

  2012cited by this paper
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

  2012cited by this paper
• Surgical salvage following stereotactic body radiotherapy for early-stage NSCLC

  2012cited by this paper
• Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.

  2012cited by this paper
• Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L).

  2012cited by this paper
• Outcomes of Stereotactic Ablative Radiotherapy in Patients With Potentially Operable Stage I Non-Small Cell Lung Cancer

  2012cited by this paper
• Diagnosis and treatment of lung cancer: summary of updated NICE guidance

  2011cited by this paper

• Impact of STAS on Lung Resections for Adenocarcinoma: A Retrospective Analysis.

  2026cites this paper
• Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study.

  2026cites this paper
• Leveraging Landmark Analysis for Tailored Surveillance in Stage I Non-Small-Cell Lung Cancer

  2026cites this paper
• Real-World Patients Management and Referral Patterns in Patients With Stage III Unresectable Non-Small Cell Lung Cancer in Poland.

  2026cites this paper
• Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial.

  2026cites this paper
• A pathomorphological complete response to neoadjuvant chemotherapy with carboplatin plus paclitaxel in stage IIIA central squamous cell carcinoma of the lung

  2026cites this paper
• Refining the PTV margin determination for VMAT SBRT lung treatment through moving target dose model to account for respiratory motion uncertainty

  2026cites this paper
• Spatial and multi-omics transcriptomic dissects platinum resistance in lung adenocarcinoma: a five-gene predictive model with tumor microenvironment dynamics.

  2026cites this paper
• Stage I non-small cell lung cancer: improving patient selection for minimally invasive lobectomy or stereotactic ablative radiotherapy based on clinical characteristics.

  2026cites this paper
• N-LODDS: A Novel Integrated Lymph Node Staging System Enhancing Prognostic Accuracy in Non-Small-Cell Lung Cancer.

  2026cites this paper
• Explainability of a Deep Learning Model for Mediastinal Lymph Node Station Classification in Endobronchial Ultrasound (EBUS).

  2026cites this paper
• Evolving Patterns of Care, Outcomes and Ongoing Challenges for Early‐Stage Non‐Small Cell Lung Cancer in the Immunotherapy Era: A Queensland Population‐Based Study

  2026cites this paper
• Upfront surgery for clinical N1 stage II non-small cell lung cancer.

  2026cites this paper
• Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.

  2026cites this paper
• Effect of preoperative inspiratory muscle training combined with education course on postoperative pulmonary complications in high-risk patients with lung cancer after video-assisted thoracoscopic surgery: a randomized controlled trial

  2026cites this paper
• The effect of radiation therapy combined with immunotherapy based on bio optical imaging on serum tumour markers and immune function in lung cancer patients: metabolic abnormality test.

  2026cites this paper
• Radiomic subtypes predict survival and chemotherapy benefit in stage I lung adenocarcinoma: a multicenter study

  2026cites this paper
• Integrated analysis reveals GSTA1 as a prognostic biomarker in stage I lung adenocarcinoma.

  2026cites this paper
• Why are patients with non-small cell lung cancer in stage I-IIIA considered inoperable? A registry-based study from the capital region of Denmark.

  2026cites this paper
• Real-world outcomes of stage III NSCLCs managed by surgery or definitive radiation therapy in the era of immunotherapy.

  2026cites this paper
• Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.

  2026cites this paper
• Unlocking the potential of immunotherapy for patients with resectable non–small cell lung cancer

  2026cites this paper
• Classification of recurrence patterns in surgically treated non-small cell lung cancer - A systematic review and a call for standardization.

  2025cites this paper
• Cadonilimab as second-line therapy in immunotherapy-resistant squamous NSCLC: a case report and review

  2025cites this paper
• 18F-FDG PET/CT Findings to Improve Confidence in Distinguishing Lung External Beam Radiotherapy Side Effects

  2025cites this paper
• Eosinopenia predicts poor outcomes in patients with lung cancer with the omicron variant of COVID-19

  2025cites this paper
• Characterization and economic burden of KRASG12C-mutant lung cancer in real-world Spanish practice: a retrospective observational study (SILK study).

  2025cites this paper
• Pulmonary rehabilitation for patients receiving lung cancer radiotherapy: a scoping review

  2025cites this paper
• Hepatic metastasis of pulmonary large cell neuroendocrine carcinoma: A case report and literature review

  2025cites this paper
• Tumor Size in Early-Stage NSCLC Is a Prognostic Factor in Single Segmentectomies but Not in Multiple Segmentectomies: A Single-Center Analysis

  2025cites this paper
• Surgical audience focused on multimodality treatment for lung cancer

  2025cites this paper
• NSCLC histological subtype classification from CT scans using generalist 3D medical foundation models

  2025cites this paper
• Neoadjuvant, Perioperative, and Adjuvant Immunotherapy in Early-Stage Surgically Resectable Non-Small Cell Lung Cancer: Updates and Future Perspectives

  2025cites this paper
• Circular RNA rising star: new findings of circPRMT5 in cancer

  2025cites this paper
• Recent technical advancements and clinical applications of MR-guided radiotherapy in lung cancer treatment

  2025cites this paper
• Enhancing Microwave Ablation for Lung Lesions with Cone-Beam Computed Tomography Guidance and Intrapulmonary Fine Adjustment in a Hybrid Operating Room.

  2025cites this paper
• Survival Analysis of Postoperative Adjuvant Chemotherapy for Stage IB Non‐Small Cell Lung Cancer Based on Racial Stratification

  2025cites this paper
• Economic Burden and Provider Referral Patterns Among Patients with Unresectable Stage III EGFR-Mutated NSCLC Receiving Chemoradiotherapy in the United States

  2025cites this paper
• Real-World Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in US Patients with Stage I–III Resected NSCLC Without Known EGFR Mutations: The RESECT Study

  2025cites this paper
• Epidemiology, patient management, and survival outcomes in resected patients with non-metastatic non-small cell lung cancer: a nationwide real-world study

  2025cites this paper
• Stereotactic body radiotherapy for central non-small cell lung cancer: risk analysis of radiation pneumonitis and bronchial dose constraints

  2025cites this paper
• Clinical TNM Lung Cancer Staging: A Diagnostic Algorithm with a Pictorial Review

  2025cites this paper
• Mediastinal staging in planning the management of patients with non-small cell lung cancer

  2025cites this paper
• No detectable impact of short-term treatment delays on lung cancer survival.

  2025cites this paper
• Meta-Analysis of the Efficacy and Safety of Sintilimab in Combination With Chemotherapy for Advanced Non–Small-Cell Lung Cancer

  2025cites this paper
• Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany

  2025cites this paper
• GALNT4 promotes the stemness of non-small cell lung cancer through O-glycosylation of MUC5AC via ITGB4/PI3K/AKT signaling pathway.

  2025cites this paper
• Latent class analysis of depression among patients with non-small cell lung cancer after surgery: A cross-sectional study

  2025cites this paper
• Clinical spectrum of lung cancer across hospitals under the National Cancer Registry Programme in India: Challenges and opportunities

  2025cites this paper
• HMGB1-BoxA gene therapy in reversing cisplatin resistance in non-small cell lung cancer

  2025cites this paper
• [18F]FDG PET/CT in the Preoperative Diagnostic and Staging of Lung Cancer—A Pictorial Evaluation

  2025cites this paper
• The importance of sophisticated techniques IMRT/VMAT: Impact on pulmonary toxicity reduction in radiotherapy of locally advanced lung cancer

  2025cites this paper
• Predicting exploratory thoracotomy in non-small cell lung cancer: a computed tomography based nomogram approach

  2025cites this paper
• Comparative diagnostic performance and safety of radial endobronchial ultrasound versus its combination with electromagnetic or virtual bronchoscopic navigation for peripheral pulmonary lesions: a retrospective study

  2025influential citation
• Prognostic Impact of KRAS-TP53 Co-Mutations in Patients with Early-Stage Non-Small Cell Lung Cancer: A Single-Center Retrospective Study

  2025cites this paper
• OM‐85, a Bacterial Lysate, Reduces Pulmonary Nodule Malignant Probability: A Retrospective Study

  2025cites this paper
• MRI-guided stereotactic body radiation therapy for very elderly patients with primary lung cancer: a retrospective analysis of safety and efficacy profiles

  2025cites this paper
• Early-stage resectable non-small cell lung cancer in Hungary

  2025cites this paper
• Recent Advances in PET and Radioligand Therapy for Lung Cancer: FDG and FAP

  2025cites this paper
• An economic evaluation of lung cancer screening with low-dose computed tomography in a high-risk population of (ex-)smokers in Belgium.

  2025cites this paper
• Healthcare Costs by Comorbidity Patterns in Lung Cancer Patients

  2025cites this paper
• The 5-year survival outcomes analysis of EGFR-TKI or/and chemotherapy as initial adjuvant therapy for completely resected IIIA non-small cell lung cancer.

  2025cites this paper
• Is SBRT the optimal first-line treatment for operable early-stage NSCLC in elderly patients?

  2025cites this paper
• Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer

  2025cites this paper
• Protocolo de manejo multimodal del cáncer de pulmón: cirugía, radioterapia y tratamiento sistémico. Indicaciones terapéuticas y paliativas de la cirugía y la radioterapia

  2025cites this paper
• Revolutionizing lung cancer treatment: harnessing exosomes as early diagnostic biomarkers, therapeutics and nano-delivery platforms

  2025cites this paper
• Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study

  2025cites this paper
• Radiation Dose Reduction in Cancer Imaging with New-Model CT Scanners: A Quality of Care Evaluation

  2025cites this paper
• Insights into lung cancer diagnosis and clinical management using [18F]F-fibroblast activation protein inhibitor (FAPI)-42 positron emission tomography/computed tomography (PET/CT)

  2025cites this paper
• Comparison of neoadjuvant chemoimmunotherapy with planned surgery and concurrent chemoradiation followed by immunotherapy for potentially resectable stage III non-small-cell lung cancer: a retrospective study

  2025cites this paper
• Impact of Different Mediastinal Staging Modalities on Target Volume Delineation in Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the Multicenter Randomized PET-Plan Trial.

  2025cites this paper
• NON-SMALL-CELL LUNG CANCER: Real-World Population-Based Cohorts’ Study

  2025cites this paper
• Is CK7 a Prognostic Marker in Pulmonary LCNEC? Evidence from a Limited Cohort Study

  2025cites this paper
• 18F-FDG PET/CT in the Preoperative Diagnostic and Staging of Lung Cancer and as a Predictor of Lymph Node Involvement

  2025cites this paper
• Advancing real-world research in thoracic malignancies: learnings from the international I-O Optimise initiative

  2025cites this paper
• Multi-gradient permutation survival analysis identifies mitosis and immune signatures steadily associated with cancer patient prognosis

  2025cites this paper
• FAPI PET in the Management of Lung Tumors.

  2025cites this paper
• Current insights into the clinico-pathologic characteristics of lung cancer in women

  2025cites this paper
• Percutaneous Cryoablation of Non-small Cell Lung Cancer in Patients with Recurrence After Stereotactic Body Radiation Therapy

  2025cites this paper
• The evolving landscape of stage III unresectable non-small cell lung cancer "between lights and shadows".

  2025cites this paper
• Dolor pleurítico y astenia en un paciente fumador

  2025cites this paper
• Non-Small Cell Lung Cancer Patients with Skip-N2 Metastases Have Similar Survival to N1 Patients—A Multicenter Analysis

  2025cites this paper
• Mediastinal staging lymph node probability map in non-small cell lung cancer

  2025cites this paper
• Real-World Evaluation of Immune-Related Endocrinopathies in Metastatic NSCLC Patients Treated with ICIs in Romania

  2025cites this paper
• Microwave ablation of non-small cell lung cancer enhances local T-cell abundance and alters monocyte interactions

  2025cites this paper
• ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach.

  2025cites this paper
• Real‐World Treatment Patterns and Associated Outcomes in Patients With Resectable Early‐Stage Non‐Small Cell Lung Cancer: The THASSOS International Study

  2025influential citation
• Evaluation of a motion correction algorithm in lung cancer PET/CT: Phantom validation and patient studies

  2025cites this paper
• Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer.

  2025cites this paper
• Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials

  2025cites this paper
• Finding patterns in lung cancer protein sequences for drug repurposing

  2025cites this paper
• Directional interactions from non-small cell lung cancer to brain glucose metabolism revealed by total-body PET imaging

  2025cites this paper
• Impact of tumor size by clinical N subclassification and histology in trimodality-treated N2 non-small cell lung cancer

  2025cites this paper
• ACR Appropriateness Criteria® Lung Cancer-Surveillance After Therapy.

  2025cites this paper
• Delphi for management of N2 non-small cell lung cancer.

  2025cites this paper
• The Role and Research Progress of Exosomes in the Pathogenesis, Diagnosis and Treatment of Lung Adenocarcinoma

  2025cites this paper
• Surgical and Perioperative Advances for Patients With Locally Advanced Non-Small Cell Lung Cancer.

  2025cites this paper
• A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer

  2025cites this paper
• β-hydroxybutyrate, a ketone body, suppresses tumor growth, stemness, and invasive phenotypes in non-small cell lung cancer.

  2025cites this paper
• Early, integrated palliative care for people with chronic respiratory disease: lessons learnt from lung cancer

  2025cites this paper